在三重调制器上改善肺功能:来自丹麦囊性纤维化队列的高分辨率全国数据
Christian Leo-Hansen1, Daniel Faurholt-Jepsen1,2, Tavs Qvist1
1Department of Infectious Diseases, Center for Cystic Fibrosis, Rigshospitalet, Copenhagen, Denmark.
ERJ open research
|December 10, 2024
概括
在患有囊性纤维化的人群中,elexacaftor/tezacaftor/ivacaftor治疗显著改善了肺功能. 这项在丹麦进行的全国性研究表明,在各种患者亚组中,持续的益处,预示着治疗结果的新时代.
科学领域:
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
- 遗传学 遗传学 是一个
背景情况:
- 丹麦为囊性纤维化患者提供了早期,普遍的elexacaftor/tezacaftor/ivacaftor三重调节器疗法.
- 全国范围内的未经选择的6岁及以上人口进行了监测,以评估治疗的影响.
研究的目的:
- 评估elexacaftor/tezacaftor/ivacaftor对肺功能和囊性纤维化疾病进展的实际影响.
- 分析不同小组的治疗效应,包括年龄,疾病严重程度和先前治疗史.
主要方法:
- 线性混合效应模型被用来分析治疗前和治疗后肺功能参数 (ppFEV1,ppFVC,ppFEF25-75%) 的变化.
- 分析了392名囊性纤维化患者的数据,包括螺旋测量测量.
- 亚组分析基于先前的调节器使用,疾病严重程度,年龄和出生队列的效应.
主要成果:
- 在12个月后,elexacaftor/tezacaftor/ivacaftor治疗导致ppFEV1的平均改善为13.0%.
- 在ppFEV1的年度变化率从治疗前的-1.4%转移到治疗期间的+2.7%.
- 在ppFVC (+8.0%) 和ppFEF25-75% (+19.5%) 中也观察到显著的改善.
结论:
- 在所有分析的子组中,现实数据显示,elexacaftor/tezacaftor/ivacaftor的肺功能得到了显著改善.
- 这项研究强调了这种疗法治疗的囊性纤维化患者的一致肺功能增长的新阶段.
相关概念视频
Cystic Fibrosis: Management
141
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
141
Cystic Fibrosis: Pathogenesis
186
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
186
COPD: Management Using Bronchodilators and Corticosteroids
178
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
178
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.5K


